SCHEMBL23083064

SCHEMBL23083064

CC(C)C1CC(=O)N(CCCCCC(=O)NCC(NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 10/20 0.43
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
PTGS1 P23219 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24588447 0.92 FOLH1 (0.42) FOLH1SMN1; SMN2HPGDHTTHDAC3
SCHEMBL24589215 0.89 FOLH1 (0.37) FOLH1SMN1; SMN2HPGDHTTHDAC3
SCHEMBL24589032 0.89 FOLH1 (0.37) FOLH1SMN1; SMN2HPGDHTTHDAC3
SCHEMBL22223311 0.88 FOLH1 (0.44) FOLH1SMN1; SMN2HPGDHTTHDAC3
SCHEMBL24589101 0.87 FOLH1 (0.39) FOLH1SMN1; SMN2HPGDHTTHDAC3
SCHEMBL24589088 0.86 FOLH1 (0.39) FOLH1SMN1; SMN2HPGDHTTHDAC3
SCHEMBL24589118 0.86 FOLH1 (0.46) FOLH1HDAC3HDAC4HDAC1HDAC7
SCHEMBL24588444 0.86 FOLH1 (0.43) FOLH1SMN1; SMN2HPGDHTTHDAC3
SCHEMBL24589218 0.85 FOLH1 (0.43) FOLH1SMN1; SMN2HPGDHTTHDAC3
SCHEMBL24588451 0.83 HDAC3 (0.46) FOLH1SMN1; SMN2HPGDHTTHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220204976-A1 RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT 2022-06-30 US disclosed
US-20210069337-A1 INTEGRIN TARGETING LIGANDS AND USES THEREOF SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT 2021-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204976-A1 RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use EPAS1, HIF1AN, HIF1A FOLH1 1272/4885SMN1; SMN2 3727/4885HPGD 1463/4885
US-20210069337-A1 INTEGRIN TARGETING LIGANDS AND USES THEREOF ITGAV, ITGA5, ITGB5 FOLH1 1914/4885SMN1; SMN2 2177/4885HPGD 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.